CervoMed plans neflamapimod 100 mg twice-daily regimen for future clinical trials
CRVO•CervoMed plans to test neflamapimod at 100 mg twice daily in future clinical trials after disclosing Phase 1 results for a new 50 mg tablet. The FDA lifted a prior plasma exposure cap, removing a constraint on dose escalation.
1. New dosing plan
CervoMed disclosed Phase 1 study results for a new neflamapimod 50 mg tablet, which is intended to provide steadier drug levels while reducing dosing frequency compared with the prior capsule. Future trials are planned to test a 100 mg twice-daily regimen, aiming for stronger expected activity with manageable tolerability.
2. Exposure cap lifted
The FDA lifted a prior plasma exposure cap, removing a key constraint on dose escalation in upcoming trials.
